Comments
Shares of Aurobindo Pharma will remain in focus on Tuesday, as it has received final nod from the US health regulator to manufacture and market the generic anti-epileptic Phenytoin Sodium capsules in the US. The product had an estimated market size of $125 million for 12 months ended April 2015, Aurobindo Pharma said quoting IMS data. The approved drug is the generic version of Pfizer Inc Parke-Davis division’s Dilantin capsules.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.